Evidence map›Paper›PMID 40678132›Full record

ArticleFrontiers in medicine2025

Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren's syndrome.

Jin-Mei Zou, Li Yang, Jia-Ang Luo, Yan Ren, Si-Yin Li, Yu Zhang, Jian-Ling Dong, Dai-Hua Deng, Yuan-Piao Ni, Min Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jin-Mei Zou *Department of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Li Yang *Department of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jia-Ang LuoDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yan RenFirst Veterans Hospital of Sichuan Province, Chengdu, China.
Si-Yin LiDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yu ZhangDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jian-Ling DongDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Dai-Hua DengDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yuan-Piao NiDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Min LiDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Xiao-Shuang YinDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jing YangDepartment of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to evaluate the efficacy of iguratimod (IGU) and hydroxychloroquine (HCQ) in the treatment of primary Sjögren's syndrome (pSS). Methods: This was a randomised controlled study. A total of 60 patients with pSS in Mianyang Central Hospital were recruited between December 2020 and December 2022. They were randomly divided into two groups: the IGU group and the HCQ group. Treatment in the IGU group was as follows: ≤10 mg of prednisone per day, 25 mg of IGU twice a day; treatment in the HCQ group was as follows: ≤10 mg of prednisone per day, 0.2 g of HCQ twice a day. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and the European League against Desiccation Sjögren's Syndrome Patient Reported Index (ESSPRI) were used to assess disease activity. Results: After 6 months of treatment, the levels of immunoglobulin G (IgG) and ESSPRI in the IGU group were significantly lower than those in the HCQ group and the levels of CD19 Conclusion: Both IGU and HCQ can reduce the disease activity and fatigue score of patients with pSS. However, IGU was superior to HCQ in reducing IgG levels. Furthermore, IGU can affect the levels of peripheral blood B lymphocytes and CD19

Indexed as

hydroxychloroquineiguratimodprimary Sjögren’s syndromeregulatory B cellstreatment

Identifiers

PMID40678132
PMCPMC12267277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.